Freenome’s Multiomics Blood Test Shows Promising Results in Detecting Colorectal Advanced Adenomas in a Prospective, Multi-Center Clinical Study
Retrieved on:
Tuesday, January 12, 2021
Compared with the FDA-approved mSEPT9 (methylated septin 9) blood test, Freenomes multiomics blood test showed much higher sensitivity (41% vs. 22%)1 for detecting AAs.
Key Points:
- Compared with the FDA-approved mSEPT9 (methylated septin 9) blood test, Freenomes multiomics blood test showed much higher sensitivity (41% vs. 22%)1 for detecting AAs.
- That means with a blood test such as Freenomes multiomics test, not only can we detect colorectal cancer, but we may be able to prevent colorectal cancer altogether.
- A blood test that can detect both advanced adenomas and early stage colorectal cancer could be an important tool in the fight against colorectal cancer.
- Importantly, these new results also showed that Freenomes multiomics blood test detected twice as many advanced adenomas as cell-free DNA methylation-only or single-protein approaches.